Bayer Group has reported a decrease in sales by 5.9% to E8 billion for the second quarter of 2009, as compared to E8.51 billion in the second quarter of 2008. The group reported 7.3% decline in net income to E532 million, as compared to E574 million in Q2, 2008.
The company has reported that the earnings before interest, taxes, depreciation and amortization before special items dropped by 6.9% to E1.76 billion, as compared to E1.89 billion in the prior year.
Bayer’s HealthCare subgroup’s second-quarter sales rose by 8.3% to E4.04 billion, as compared to E3.73 billion in 2008. Sales in the Pharmaceuticals segment rose by 9.1% to E2.63 billion.
The company claims that the strongest gains were recorded by the general medicine business unit, followed by specialty medicine, diagnostic imaging and women’s healthcare. The sales of the consumer health segment increased by 6.9%, to E1.41 billion, as compared to the second quarter of 2008. Group sales fell by 6.7% to E15.90 billion, as compared to 17.04 billion in 2008.